Shin Poong Pharm.Co.Ltd.
Shinpoong Pharmaceutical Co.,Ltd, together with its subsidiaries, manufactures and sells pharmaceutical products in South Korea. The company offers cephalosporin antibiotics; penicillin antibiotics; and finished products, as well as antivirals, anticancer drugs, painkillers, anti-inflammatory products, and anthelmintics. It provides active pharmaceutical ingredients; Pyramax, an anti-malarial dru… Read more
Shin Poong Pharm.Co.Ltd. (019170) - Net Assets
Latest net assets as of September 2025: ₩264.20 Billion KRW
Based on the latest financial reports, Shin Poong Pharm.Co.Ltd. (019170) has net assets worth ₩264.20 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩341.59 Billion) and total liabilities (₩77.39 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩264.20 Billion |
| % of Total Assets | 77.34% |
| Annual Growth Rate | 5.22% |
| 5-Year Change | -31.05% |
| 10-Year Change | 32.45% |
| Growth Volatility | 18.21 |
Shin Poong Pharm.Co.Ltd. - Net Assets Trend (2003–2024)
This chart illustrates how Shin Poong Pharm.Co.Ltd.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Shin Poong Pharm.Co.Ltd. (2003–2024)
The table below shows the annual net assets of Shin Poong Pharm.Co.Ltd. from 2003 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩258.09 Billion | -4.69% |
| 2023-12-31 | ₩270.78 Billion | -18.13% |
| 2022-12-31 | ₩330.76 Billion | -6.71% |
| 2021-12-31 | ₩354.56 Billion | -5.28% |
| 2020-12-31 | ₩374.33 Billion | +79.00% |
| 2019-12-31 | ₩209.13 Billion | +0.79% |
| 2018-12-31 | ₩207.48 Billion | -1.25% |
| 2017-12-31 | ₩210.11 Billion | -3.11% |
| 2016-12-31 | ₩216.85 Billion | +11.28% |
| 2015-12-31 | ₩194.86 Billion | +1.75% |
| 2014-12-31 | ₩191.51 Billion | +0.38% |
| 2013-12-31 | ₩190.79 Billion | +1.09% |
| 2012-12-31 | ₩188.73 Billion | +4.93% |
| 2011-12-31 | ₩179.86 Billion | +19.59% |
| 2010-12-31 | ₩150.39 Billion | +3.50% |
| 2009-12-31 | ₩145.31 Billion | +13.58% |
| 2008-12-31 | ₩127.93 Billion | +12.41% |
| 2007-12-31 | ₩113.81 Billion | +7.09% |
| 2006-12-31 | ₩106.28 Billion | +8.83% |
| 2005-12-31 | ₩97.65 Billion | +11.78% |
| 2004-12-31 | ₩87.36 Billion | -1.39% |
| 2003-12-31 | ₩88.59 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Shin Poong Pharm.Co.Ltd.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 3894326103000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩38.94 Billion | 15.16% |
| Other Components | ₩217.88 Billion | 84.84% |
| Total Equity | ₩256.82 Billion | 100.00% |
Shin Poong Pharm.Co.Ltd. Competitors by Market Cap
The table below lists competitors of Shin Poong Pharm.Co.Ltd. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
VIP Industries Limited
NSE:VIPIND
|
$255.94 Million |
|
Shenyang Brilliant Elevator Group Co Ltd
SHE:002689
|
$255.98 Million |
|
Unizyx Holding Corp
TW:3704
|
$256.10 Million |
|
IZDEMIR Enerji Elektrik Uretim A.S.
IS:IZENR
|
$256.11 Million |
|
Hailun Piano Co Ltd
SHE:300329
|
$255.90 Million |
|
Wagners Holding Company Ltd
AU:WGN
|
$255.88 Million |
|
BELLSYSTEM24 HLDGS O.N.
F:B24
|
$255.84 Million |
|
LAY-OUT Planning Consultants Co. Ltd.
SHE:300989
|
$255.83 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Shin Poong Pharm.Co.Ltd.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 269,585,828,030 to 256,820,523,460, a change of -12,765,304,570 (-4.7%).
- Net loss of 15,387,261,000 reduced equity.
- Other factors increased equity by 2,621,956,430.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-15.39 Billion | -5.99% |
| Other Changes | ₩2.62 Billion | +1.02% |
| Total Change | ₩- | -4.74% |
Book Value vs Market Value Analysis
This analysis compares Shin Poong Pharm.Co.Ltd.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.11x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 2.51x to 2.11x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | ₩4372.79 | ₩10980.00 | x |
| 2018-12-31 | ₩4303.11 | ₩10980.00 | x |
| 2019-12-31 | ₩4338.83 | ₩10980.00 | x |
| 2020-12-31 | ₩7577.91 | ₩10980.00 | x |
| 2021-12-31 | ₩7174.44 | ₩10980.00 | x |
| 2022-12-31 | ₩6689.68 | ₩10980.00 | x |
| 2023-12-31 | ₩5471.49 | ₩10980.00 | x |
| 2024-12-31 | ₩5212.40 | ₩10980.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Shin Poong Pharm.Co.Ltd. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -5.99%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -6.96%
- • Asset Turnover: 0.65x
- • Equity Multiplier: 1.33x
- Recent ROE (-5.99%) is below the historical average (3.37%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2003 | 15.04% | 10.49% | 0.76x | 1.89x | ₩4.43 Billion |
| 2004 | 1.53% | 0.94% | 0.81x | 2.01x | ₩-7.38 Billion |
| 2005 | 12.08% | 7.71% | 0.80x | 1.95x | ₩2.03 Billion |
| 2006 | 20.57% | 13.74% | 0.79x | 1.90x | ₩11.21 Billion |
| 2007 | 7.33% | 5.02% | 0.76x | 1.91x | ₩-3.03 Billion |
| 2008 | 8.91% | 6.04% | 0.70x | 2.11x | ₩-1.40 Billion |
| 2009 | 13.71% | 9.15% | 0.70x | 2.14x | ₩5.37 Billion |
| 2010 | 13.67% | 8.84% | 0.72x | 2.14x | ₩5.51 Billion |
| 2011 | 13.07% | 10.22% | 0.61x | 2.11x | ₩5.51 Billion |
| 2012 | 7.21% | 6.14% | 0.58x | 2.01x | ₩-5.26 Billion |
| 2013 | 2.69% | 2.38% | 0.54x | 2.09x | ₩-13.92 Billion |
| 2014 | 1.65% | 1.44% | 0.54x | 2.14x | ₩-15.96 Billion |
| 2015 | 0.76% | 0.75% | 0.48x | 2.12x | ₩-17.87 Billion |
| 2016 | -8.59% | -9.58% | 0.47x | 1.92x | ₩-40.25 Billion |
| 2017 | 0.43% | 0.49% | 0.48x | 1.84x | ₩-20.08 Billion |
| 2018 | 1.36% | 1.50% | 0.49x | 1.85x | ₩-17.84 Billion |
| 2019 | 2.56% | 2.81% | 0.50x | 1.83x | ₩-15.49 Billion |
| 2020 | 1.34% | 2.53% | 0.41x | 1.30x | ₩-32.33 Billion |
| 2021 | -3.28% | -6.12% | 0.48x | 1.11x | ₩-46.93 Billion |
| 2022 | -10.73% | -16.90% | 0.58x | 1.10x | ₩-68.34 Billion |
| 2023 | -21.26% | -28.63% | 0.57x | 1.30x | ₩-84.28 Billion |
| 2024 | -5.99% | -6.96% | 0.65x | 1.33x | ₩-41.07 Billion |
Industry Comparison
This section compares Shin Poong Pharm.Co.Ltd.'s net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $185,563,423,740
- Average return on equity (ROE) among peers: 1.60%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Shin Poong Pharm.Co.Ltd. (019170) | ₩264.20 Billion | 15.04% | 0.29x | $255.90 Million |
| Dongwha Pharm.Co.Ltd (000020) | $229.73 Billion | 2.15% | 0.36x | $75.32 Million |
| Yuhan Corp. (000100) | $323.58 Billion | 10.19% | 0.72x | $4.21 Billion |
| Yuyu Pharma Inc (000227) | $128.69 Billion | -1.72% | 0.50x | $26.44 Million |
| Ildong Holdings Co Ltd (000230) | $66.98 Billion | 10.88% | 1.80x | $49.55 Million |
| Samil Pharm (000520) | $62.87 Billion | 0.00% | 0.77x | $110.58 Million |
| Donga Socio Holdings (000640) | $328.69 Billion | 10.58% | 1.17x | $206.35 Million |
| Jw Pharmac (001060) | $223.83 Billion | 0.28% | 1.65x | $278.34 Million |
| JW Pharmaceutical Corp (001067) | $265.44 Billion | 13.94% | 1.43x | $489.75 Million |
| Samsung Pharm (001360) | $77.58 Billion | -31.98% | 0.20x | $65.82 Million |
| Ahn-Gook Pharmaceutical Co. Ltd (001540) | $148.25 Billion | 1.71% | 0.47x | $27.39 Million |